论文部分内容阅读
目的:探讨沐舒坦在极低出生体重儿中防治新生儿肺透明膜病(HMD)的临床价值。方法:经沐舒坦+固尔苏治疗的32例极低出生体重儿,与同期经单次固尔苏治疗的36例极低出生体重儿进行比较,观察HMD发生率、严重程度以及死亡率和CPAP机械通气时间的差异。结果:沐舒坦+固尔苏组和固尔苏组的HMD发生率分别为21.8%和47.2%(X2=4.766,P<0.05),死亡率为3.1%和8.3%(X2=0.830,P>0.05);CPAP/机械通气时间分别为13.14±5.63小时和29.88±19.23小时(t=-2.237,P<0.05);沐舒坦+固尔苏组HMD患儿中I级3例,Ⅱ级2例,Ⅲ级和Ⅳ级各1例,固尔苏组HMD患儿中,I级5例,II级6例,Ⅲ级4例,Ⅳ级2例(U=423.00,P<0.05)。结论:与单次使用固尔苏相比,加用沐舒坦能降低极低出生体重儿的HMD发生率和严重程度,并能减少CPAP机械通气时间时间,从而减少固尔苏的重复使用,值得在基层医院和经济欠发达地区推广。
Objective: To investigate the clinical value of ambroxol in the prevention and treatment of neonatal hyaline membrane disease (HMD) in very low birth weight infants. Methods: Thirty-two cases of very low birth weight infants treated with mucosolvan and celbuterol were compared with 36 very low birth weight infants treated with single-dose cortisone. The incidence, severity and mortality of HMD were observed Differences in CPAP mechanical ventilation time. Results: The incidence of HMD was 21.8% and 47.2% in Mucosolvan + Guer Su Su group and Guer Su Su group respectively (X2 = 4.766, P <0.05), and the mortality rates were 3.1% and 8.3% 0.05). The time of CPAP / mechanical ventilation was 13.14 ± 5.63 hours and 29.88 ± 19.23 hours respectively (t = -2.237, P <0.05). There were 3 cases of grade I and 2 cases of grade Ⅱ in patients with HMD , Grade Ⅲ and grade Ⅳ in 1 case. Among the children with HMD, there were 5 cases of grade I, 6 cases of grade II, 4 cases of grade III and 2 cases of grade IV (U = 423.00, P <0.05). CONCLUSIONS: Compared with single-dose glufosinate, the addition of ambrosal can reduce the incidence and severity of HMD in very-low birth weight infants and reduce the time and duration of CPAP mechanical ventilation, thereby reducing the re-use of glucocorticolate, which is worth In primary care hospitals and economically underdeveloped areas to promote.